Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors?

Journal of Clinical Oncology

Volumn 22, Issue 3, 2004, Pages 573-

  Völter, Verena ^a   Peschel, Christian ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; DRUG DERIVATIVE; SOMATOSTATIN;

CLINICAL TRIAL; GASTROINTESTINAL TUMOR; HUMAN; METASTASIS; NEUROENDOCRINE TUMOR; NOTE; PANCREAS TUMOR; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; GASTROINTESTINAL NEOPLASMS; HUMANS; INTERFERON ALFA-2A; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 1442265900     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2004.99.175     Document Type: Letter

References (5)

1. Faiss S, Pape UF, Böhmig M, et al: Prospective, randomized, mulitcenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropathic tumors: The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21: 2689-2696, 2003
2. Frank M, Klose KJ, Wied M, et al: Combination therapy with octreotide and alpha-interferon: Effect on tumor growth in metastatic endocrine gastroenteropathic tumors. Am J Gastroenterol 94: 1381-1387, 1999
3. Ducreux M, Ruszniewksi P, Chayvialle JA, et al: The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95: 3276-3281, 2000
4. Aparicio T, Ducreux M, Baudin E, et al: Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 37: 1014-1019, 2001
5. O'Toole D, Ducreux M, Bommelaer G, et al: Treatment of carcinoid syndrome: A prospective cross-over evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88: 770-776, 2000